When a person is already living with a cancer diagnosis, one of the most common questions is: When can a liquid biopsy complement cancer follow-up? The concern usually comes from something very specific: it is not always easy to interpret changes in the images, and sometimes an earlier signal is needed to know if the tumor is responding, if therapeutic resistance appears or if there is a risk of recurrence. In this context, liquid biopsy provides molecular data that can accompany control with CT scans, MRIs and serum markers.
Liquid biopsy is a noninvasive test based on a sample of blood (and in certain tumors also urine or other fluids) that looks for signs of the tumor circulating in the bloodstream. Its value in oncological follow-up is in detecting genetic or epigenetic variations that may appear before visible changes in diagnostic imaging, which helps to refine clinical decisions.
What is liquid biopsy and how does it work in cancer monitoring?
Liquid biopsy analyzes tumor material that is released into body fluids. The most common is to study blood, where fragments of circulating free DNA (cfDNA) and, within this group, circulating tumour DNA (ctDNA) can be found. The presence of circulating tumor cells, which are malignant cells that travel through the vascular system, can also be detected.
In follow-up, the logic is simple: if the tumor grows, changes, or develops resistance, these variations are usually reflected in the biomarkers detectable in the blood. With sequencing and bioinformatic analysis technologies, mutations are identified, levels are quantified and results are compared over time.
Circulating tumor cells and circulating tumor DNA (ctDNA)
The circulating tumor cells come from the primary or metastatic tumor. By isolating them, their profile can be studied and signs of tumour evolution can be observed. They are not always easily detected, but in some scenarios they provide relevant clinical information.
ctDNA are DNA fragments released by cancer cells, often during cell death processes. By containing mutations from the original tumor, it allows genetic changes to be tracked without entering the tissue. In terms of evidence, Nature Reviews Clinical Oncology describes that ctDNA can be detected in advanced cancer with high sensitivity, which supports its role as an adjunct to follow-up.
Differences between liquid biopsy and tissue biopsy in cancer control
Tissue biopsy requires an invasive procedure to sample the tumor. This can be complex if the lesion is in a difficult area or if the patient is not in a position to repeat frequent procedures. Liquid biopsy is based on a simple venous extraction, which allows more regular controls with less burden on the patient.
At the information level, tissue biopsy shows what is happening in a specific area of the tumour (local heterogeneity). Liquid biopsy reflects a more “global” signal of cancer in the body, including metastasis activity that may not yet be clearly seen in images.
Clinical scenarios where liquid biopsy complements follow-up
The real usefulness appears when conventional follow-up falls short or when molecular data is needed to guide clinical conduct. It does not replace diagnostic imaging, but it can add a different angle.
Monitoring the response to cancer treatment
During chemotherapy, radiation therapy, or targeted therapies, ctDNA tends to go down when the tumor responds. This decrease can be observed weeks before a CT scan shows a reduction in size, because the images usually capture later morphological changes.
With this early signal, the treating team can assess whether to maintain the scheme, whether to intensify surveillance or whether to study other options when the response is not as expected, seeking to avoid treatment cycles with a low probability of benefit.
Early detection of therapeutic resistance
A frequent problem in cancer follow-up is that cancer learns to dodge treatments. The appearance of new mutations in ctDNA may indicate therapeutic resistance even if the patient does not yet have marked clinical progression.
This point is relevant because it allows us to anticipate. If biomarkers of resistance are detected, a change in strategy (depending on the type of tumor, stage, and available options) may be considered. Genetic panels should be selected judiciously, as relevant mutations vary depending on the cancer and treatment received.
Tumor burden assessment during chemotherapy
ctDNA quantification can function as an estimate of systemic tumor burden. This complements traditional tumor markers, which are not always elevated or non-existent for certain tumors.
When the serum marker doesn’t help, ctDNA can offer a quantifiable signal to compare over time. Still, it is always interpreted in conjunction with symptoms, physical examination, imaging, and other available biomarkers.
Liquid biopsy to detect minimal residual disease
Residual molecular disease (or minimal residual disease) refers to tumor cells remaining after treatment with curative intent. These cells may be microscopic and not seen in conventional studies, but over time they can cause recurrence.
Post-treatment surveillance using cfDNA
After surgery or curative treatments, finding persistent tumor cfDNA may suggest that residual disease remains. This may lead to adjusting the plan, intensifying post-treatment surveillance or evaluating adjuvant therapies depending on the case. In the literature, the Journal of Clinical Oncology has described the usefulness of cfDNA in detecting early recurrence in several types of cancer.
Molecular detection of recurrence before imaging
One of the most sought-after contributions in follow-up is to detect early recurrence. Liquid biopsy can identify molecular signals months before a lesion is visible radiologically, especially when the tumor burden is low.
Detecting recurrence early can expand therapeutic alternatives. The key is to interpret the finding with clinical caution: a molecular change does not always equate to a confirmed relapse, and usually requires correlation with imaging and complete medical evaluation.
Types of cancer where it is most effective for follow-up
The performance of liquid biopsy is not identical in all cancers. The stage, biology of the tumor, how much DNA is released into the bloodstream, and the site of the disease all play a role.
Usefulness in metastatic breast cancer and early stages
In breast cancer, liquid biopsy can detect mutations such as ESR1, PIK3CA and TP53. This information can guide hormonal sensitivity, clonal evolution and therapeutic resistance. In metastatic disease, ctDNA levels usually correlate with response to anti-HER2 and hormonal treatments, helping to monitor changes more closely.
In the early stages, the challenge is sensitivity: if the tumour is small, there may be less circulating ctDNA and the result may be negative even if there is disease.
Applications in pancreatic and bladder cancer
Pancreatic cancer, due to its aggressive biological behavior, usually releases more ctDNA, which facilitates detection in the blood compared to low-release tumors. In bladder cancer, urine can complement the blood test, improving sensitivity in certain follow-up scenarios, especially when the tumor is in direct contact with the urinary tract.
Biomarkers according to tumor type
Biomarkers depend on the tumor. Common examples include KRAS mutations in colorectal cancer, EGFR alterations in lung cancer, and HER2 amplifications in breast cancer. DNA methylation also provides epigenetic information that can help characterise tumour behaviour or subtypes, expanding the scope of follow-up.
Limitations of liquid biopsy in oncological control
Although it is a powerful tool, it should not be sold as a “substitute” for conventional tracking. It has technical and clinical limits that influence its interpretation.
Reduced sensitivity in early stages
In early cancer, ctDNA can be so low that it goes undetected. In this scenario, a negative result does not rule out disease. For this reason, follow-up is usually supported by diagnostic imaging, clinical evaluation and, when it adds value, liquid biopsy as a complement.
False negatives and their clinical interpretation
False negatives occur when the tumour releases little DNA, when the tumour burden is minimal or when there are biological barriers, such as in tumours of the central nervous system where the blood-brain barrier limits the passage of tumour material into the blood. For this reason, the results are assessed with the full picture: symptoms, images, evolution and history of cancer treatment.
When to Confirm Results with Tissue Biopsy
If there is a discordance between liquid biopsy and imaging, or if the therapeutic change is large and sustained only by a molecular finding, confirmation with tissue biopsy is usually considered when feasible. This is especially important if it is necessary to characterize the tumor in detail, verify a key mutation, or rule out pre-analytical errors.
Current technologies and techniques for monitoring
Accuracy depends a lot on the technology used, the type of genetic panel, the quality control of the laboratory and the interpretation of the result.
Bioinformatic analysis and mutation detection
Next-generation sequencing allows the detection of somatic variants with high sensitivity. Bioinformatic analysis helps distinguish real mutations of the tumor against germline variants or technical artifacts. Cancer Discovery has described advances in ctDNA analysis methodologies aimed at improving diagnostic accuracy.
DNA methylation as a complementary biomarker
DNA methylation observes epigenetic changes that are not classical mutations. It can provide signals on tumor origin, behavior, and subtypes, and is considered a valuable complement when the mutation panel does not provide a clear answer or when seeking to expand sensitivity in follow-up.
Alternative samples: blood, urine, and other body fluids
Blood is the standard sample. Urine is relevant in genitourinary tumors. In specific situations, other fluids (such as cerebrospinal or pleural fluid) may be more informative depending on the location of the cancer and the clinical goal of follow-up.
Integration of oncological follow-up into clinical practice
For this test to bring real value in Panama, orderly integration is needed. It is not a matter of having repeated analyses without a plan, but of defining objectives: response, therapeutic resistance, tumour burden, residual molecular disease or suspected recurrence.
Recommended frequency of liquid biopsy checkups
The periodicity changes depending on the scenario. In active treatment, it may be considered every 2 to 4 weeks when the goal is to see early ctDNA trend. In post-treatment surveillance, the intervals are usually wider, such as every 3 to 6 months, always aligned with clinical controls and imaging.
Interpretation along with imaging studies
The safest reading arises when integrating liquid biopsy with diagnostic imaging. If the ctDNA goes up and the image is stable, it may indicate early molecular change or also technical variations, so it is advisable to repeat, correlate and monitor. If the image progresses and the ctDNA does not change, it may be low DNA release or a tumor with a molecular signal that is difficult to capture in the blood.
Future of liquid biopsy in cancer management
Greater sensitivity is expected for early stages, more complete panels and automation supported by artificial intelligence to interpret results. Nature Medicine has highlighted the potential of liquid biopsy to change cancer follow-up in the coming years. Even with advances, the key will continue to be the correct clinical use: choosing well when to order it and how to act with the result.
FAQ: Frequently Asked Questions about Liquid Biopsy in Cancer Follow-Up
¿La biopsia líquida reemplaza las tomografías o resonancias en el seguimiento?
No. Diagnostic imaging remains essential to see location, lesion size, and organ involvement. Liquid biopsy is interpreted as a molecular adjunct, useful for anticipating changes and understanding mutations or therapeutic resistance.
¿Qué detecta exactamente una biopsia líquida: ctDNA, cfDNA o células tumorales circulantes?
It can measure total cfDNA and look within it for ctDNA with tumor mutations. Circulating tumor cells are also detected in certain assays. The type of analysis depends on the panel, the technology, and the clinical goal of follow-up.
¿Puede identificar resistencia terapéutica aunque las imágenes se vean estables?
Yes, in some cases resistance mutations appear in ctDNA before progression is seen on images. This does not imply an automatic change of treatment; It is evaluated along with clinical findings, diagnostic imaging, and other tests.
¿Sirve para detectar enfermedad molecular residual después de cirugía o tratamiento curativo?
It can be helpful. The persistent presence of tumor signal in cfDNA or ctDNA may suggest minimal residual disease and help to decide on closer post-treatment surveillance or to consider additional therapies as appropriate.
¿Qué tan confiable es en cáncer temprano?
Its reduced sensitivity in early stages is a recognized limitation. A negative result does not rule out cancer or rule out recurrence if the tumor burden is low. That is why it is combined with imaging studies, clinical controls and, when appropriate, tissue biopsy.
¿Qué pasa si el resultado de la biopsia líquida contradice lo que muestran las imágenes?
The full context is reviewed. It can be an early signal not yet visible, or a technical or biological false negative/positive. When the result changes the course of treatment, confirmation with tissue biopsy is usually considered if feasible.
¿Cada cuánto se recomienda repetirla durante el tratamiento oncológico?
It depends on the plan and the objective. In active therapy, some regimens include controls every 2 to 4 weeks to see a trend in ctDNA. In surveillance, the intervals are usually extended to 3 to 6 months, coordinated with the calendar of images and consultations.
Liquid biopsy makes more sense when it is ordered with a clear clinical question and interpreted with the rest of the oncological follow-up, without depending on a single piece of data. Well integrated, it can provide early detection of molecular changes, guide therapeutic resistance and support post-treatment surveillance. With this practical vision, it becomes an ally for more timely and better informed decisions.
In practice, when can a liquid biopsy complement oncological follow-up? when a molecular signal is needed to assess response, resistance, minimal residual disease, or recurrence along with imaging and clinical evaluation.
